Developing a new drug requires that life sciences companies invest vast amounts of resources. Depending on the complexity of treatment, firms can devote over a decade to the R&D process. In terms of financial cost, a single drug can require hundreds of millions of dollars from start to finish. Considering […]
Inflammatory bowel disease (IBD) affects more than 1.4 million people in the United States alone. While IBD is often confused with irritable bowel syndrome, the two conditions are not the same. This isn’t to diminish irritable bowel syndrome, which can cause serious gastrointestinal discomfort. It simply doesn’t lead to the same visible inflammation and damage in the intestines that we usually see in IBD. IBD manifests in various forms, but the two most common—and well-known—types are Crohn’s disease and ulcerative colitis. Cases of Crohn’s disease, in particular, are increasing, supporting the need to find an effective course of treatment for the condition.